金政文-河清海宴网

中药出海不可小觑另一方面，

估值，该换一套模型了拥有创新药+

被忽略的研发型增长逻辑这样的节

-仅化药管线中两款临近上市品种（

研发不是烧钱，是蓄力在一众中药企

Well done! You successfully read this important alert message.

Heads up! This alert needs your attention, but it's not super important.

Warning! Best check yo self, you're not looking too good.

Oh snap! Change a few things up and try submitting again.

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration

这种上市一批、申报一批、在研一批的节奏，在国内中药企业中并不多见。.appendQr_wrap{border:1pxsolid#E6E6E6;padding:8px;}.appendQr_normal{float

若以分部估值视角看：-成熟业务年利润约16亿对应15倍PE，即240亿市值.appendQr_wrap{border:1pxsolid#E6E6E6;padding:8px;}.appendQr_normal{float:left;}.appendQr_normali

被忽略的研发型增长逻辑这样的节奏在国内中药企

依托这样的科研实力，以岭药业创新中药管线成果频

h1. Bootstrap heading